At a glance
- Originator Encysive Pharmaceuticals
- Class Antiasthmatics; Antihyperlipidaemics; Antirheumatics
- Mechanism of Action Integrin alpha4beta1 antagonists; Vascular cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Atherosclerosis; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 14 May 2001 Discontinued-Preclinical for Asthma in USA (Unknown route)
- 14 May 2001 Discontinued-Preclinical for Atherosclerosis in USA (Unknown route)
- 14 May 2001 Discontinued-Preclinical for Multiple sclerosis in USA (Unknown route)